Overview

Double Randomized and Placebo Controlled Trail of Sanchitongshu Combined Antiplatelet Drug to Prevent Ischemic Stroke

Status:
Unknown status

Trial end date:
2020-12-31

Target enrollment:

Participant gender:

Summary

This clinical trail will evaluate the effect of Sanchitongshu combined with antiplatelet drugs (Aspirin or Clopidogrel) in the treatment of high-risk ischemic stroke patients in adults. Half of participants will receive SanchiTongshu and one of antiplatelet drugs (Aspirin or Clopidogrel) in combination, while the other half will receive a placebo and one of antiplatelet drugs (Aspirin or Clopidogrel).

Phase:

N/A

Details

Lead Sponsor:

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Treatments:

Aspirin
Clopidogrel
Platelet Aggregation Inhibitors